{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-dummy+placebo&page=8", "query": { "intervention": "Double-dummy placebo", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 370, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-dummy+placebo&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-dummy+placebo&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T11:56:59.000Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01076764", "title": "Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Otamixaban", "type": "DRUG" }, { "name": "Placebo (for Otamixaban)", "type": "DRUG" }, { "name": "UFH", "type": "DRUG" }, { "name": "Placebo (for UFH)", "type": "DRUG" }, { "name": "Eptifibatide", "type": "DRUG" }, { "name": "Placebo (for Eptifibatide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13220, "start_date": "2010-04", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 107, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076764" }, { "nct_id": "NCT01358578", "title": "Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "secukinumab (AIN457)", "type": "DRUG" }, { "name": "etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1306, "start_date": "2011-06", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358578" }, { "nct_id": "NCT00235820", "title": "Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "adalimumab", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "placebo adalimumab, placebo MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-07-17", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 1, "location_summary": "Abbott Park, Illinois", "locations": [ { "city": "Abbott Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235820" }, { "nct_id": "NCT01046214", "title": "Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Depressive Disorder" ], "interventions": [ { "name": "Bupropion HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 8, "start_date": "2010-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 2, "location_summary": "Culver City, California • Glendale, California", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01046214" }, { "nct_id": "NCT04020341", "title": "A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Tract Infections" ], "interventions": [ { "name": "Gepotidacin", "type": "DRUG" }, { "name": "Placebo matching nitrofurantoin", "type": "DRUG" }, { "name": "Nitrofurantoin", "type": "DRUG" }, { "name": "Placebo matching gepotidacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "FEMALE", "summary": "12 Years and older · Female only" }, "enrollment_count": 1531, "start_date": "2019-10-17", "completion_date": "2022-11-30", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020341" }, { "nct_id": "NCT03904693", "title": "Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)" ], "interventions": [ { "name": "FDC macitentan/tadalafil", "type": "DRUG" }, { "name": "Macitentan 10 mg", "type": "DRUG" }, { "name": "Tadalafil 40 mg", "type": "DRUG" }, { "name": "Placebo FDC", "type": "DRUG" }, { "name": "Placebo macitentan", "type": "DRUG" }, { "name": "Placebo tadalafil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actelion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2019-07-29", "completion_date": "2024-09-27", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 26, "location_summary": "Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03904693" }, { "nct_id": "NCT00819585", "title": "A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Colchicine", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "Placebo Matching Canakinumab", "type": "DRUG" }, { "name": "Placebo Matching Colchicine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 432, "start_date": "2008-12", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2018-07-17", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 19, "location_summary": "Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819585" }, { "nct_id": "NCT01512160", "title": "Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-surgical Dental Pain" ], "interventions": [ { "name": "PF-04531083", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Ibuprofen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 90, "start_date": "2011-10", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01512160" }, { "nct_id": "NCT01899144", "title": "Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Albuterol Spiromax", "type": "DRUG" }, { "name": "ProAir HFA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Years to 11 Years" }, "enrollment_count": 61, "start_date": "2013-07", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2022-01-26", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Alaska" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01899144" }, { "nct_id": "NCT05814627", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib Matching Placebo", "type": "DRUG" }, { "name": "Adalimumab Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 487, "start_date": "2023-06-15", "completion_date": "2026-07-15", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-11T11:56:59.000Z", "location_count": 85, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814627" } ] }